The Characteristics of Metallo-beta-Lactamase-Producing Gram-Negative Bacilli Isolated from Sputum and Urine: A Single Center Experience in Korea.
10.3349/ymj.2011.52.2.351
- Author:
Bum Sik CHIN
1
;
Sang Hoon HAN
;
Suk Hoon CHOI
;
Han Sung LEE
;
Su Jin JEONG
;
Hee Kyung CHOI
;
Jun Yong CHOI
;
Young Goo SONG
;
Chang Ki KIM
;
Dongeun YONG
;
Kyungwon LEE
;
June Myung KIM
Author Information
1. AIDS Research Institute and Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. jmkim@yuhs.ac
- Publication Type:Brief Communication ; Research Support, Non-U.S. Gov't
- Keywords:
Metallo-beta-lactamase;
risk factor;
resistance
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Anti-Bacterial Agents/pharmacology/therapeutic use;
Child;
Child, Preschool;
Electrophoresis, Gel, Pulsed-Field;
Female;
Gram-Negative Bacteria/drug effects/*enzymology/isolation & purification;
Gram-Negative Bacterial Infections/drug therapy/enzymology/microbiology;
Humans;
Male;
Microbial Sensitivity Tests;
Middle Aged;
Republic of Korea;
Sputum/*microbiology;
Urine/*microbiology;
beta-Lactam Resistance;
beta-Lactamases/*metabolism
- From:Yonsei Medical Journal
2011;52(2):351-357
- CountryRepublic of Korea
- Language:English
-
Abstract:
Metallo-beta-lactamase (MBL) production usually results in high-level resistance to most beta-lactams, and a rapid spread of MBL producing major gram-negative pathogens is a matter of particular concern worldwide. However, clinical data are scarce and most studies compared MBL producer (MP) with MBL non-producer (MNP) strains which included carbapenem susceptible isolates. Therefore, we collected clinical data of patients in whom imipenem-nonsusceptible Pseudomonas aeruginosa (PA) and Acinetobacter baumannii (AB) were isolated from sputum or urine, and investigated MBL production and the risk factors related with MBL acquisition. The antimicrobial susceptibility patterns were also compared between MPs and imipenem-nonsusceptible MNPs (INMNP). Among the 176 imipenem-nonsusceptible isolates, 12 MPs (6.8%) were identified. There was no identifiable risk factor that contributed to the acquisition of MPs when compared to INMNPs, and case-fatalities were not different between the two groups. The percentage of susceptible isolates was higher among MPs for piperacilin/tazobactam and fluoroquinolones while that of ceftazidime was higher in INMNPs (p < 0.05). As regards to aztreonam, which has been known to be a uniquely stable beta-lactam against MBLs, susceptibility was preserved in only two isolates (16.7%) among MPs, and was not higher than that of INMNPs (23.2%). In conclusion, the contribution of MBLs to imipenem non-susceptibility in PA/ABs isolated from sputum and urine was relatively limited, and there was no significant risk factor associated with acquisition of MPs compared with INMNPs. However, limited susceptibility to aztreonam implies that MPs may hold additional resistance mechanisms, such as extended spectrum beta-lactamases, AmpC beta-lactamases, or other non-enzymatic mechanisms.
